Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis.
about
Eliminating the Neglected Tropical Diseases: Translational Science and New Technologies.Leishmania spp. Proteome Data Sets: A Comprehensive Resource for Vaccine Development to Target Visceral LeishmaniasisImaging African trypanosomesRecombinant vaccines against T. gondii: comparison between homologous and heterologous vaccination protocols using two viral vectors expressing SAG1Cytotoxic T cells mediate pathology and metastasis in cutaneous leishmaniasisBiomarkers of safety and immune protection for genetically modified live attenuated leishmania vaccines against visceral leishmaniasis - discovery and implications.A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine InfectionAssessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposureVaccines to prevent leishmaniasis.Polymorphism in the HASPB repeat region of East African Leishmania donovani strainsComparison of visceral leishmaniasis diagnostic antigens in African and Asian Leishmania donovani reveals extensive diversity and region-specific polymorphismsPrediction of CD8+ Epitopes in Leishmania braziliensis Proteins Using EPIBOT: In Silico Search and In Vivo Validation.Intradermal Immunization of Leishmania donovani Centrin Knock-Out Parasites in Combination with Salivary Protein LJM19 from Sand Fly Vector Induces a Durable Protective Immune Response in Hamsters.Sequential chemoimmunotherapy of experimental visceral leishmaniasis using a single low dose of liposomal amphotericin B and a novel DNA vaccine candidate.Characterization of the biology and infectivity of Leishmania infantum viscerotropic and dermotropic strains isolated from HIV+ and HIV- patients in the murine model of visceral leishmaniasis.Coadministration of cruzipain and GM-CSF DNAs, a new immunotherapeutic vaccine against Trypanosoma cruzi infection.N-Myristoyltransferase as a potential drug target in malaria and leishmaniasis.Immunity to visceral leishmaniasis: implications for immunotherapy.DNA vaccine against visceral leishmaniasis: a promising approach for prevention and control.Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis.[Leishmania epidemiology, diagnosis, chemotherapy and vaccination approaches in the international network of Pasteur Institutes].Visceral Leishmaniasis Control and Elimination: Is There a Role for Vaccines in Achieving Regional and Global Goals?Evaluation of a novel lentiviral vaccine expressing KMP11-HASPB fusion protein against Leishmania infantum in BALB/c mice.Exploring the Leishmania Hydrophilic Acylated Surface Protein B (HASPB) Export Pathway by Live Cell Imaging Methods.Peptide Vaccines for Leishmaniasis.
P2860
Q26765026-F8C588C8-420E-4558-9D82-3E311263916BQ26858852-51F46345-503A-40F2-A914-F1F19A80C6E6Q27010326-B5D3281C-EC1A-4240-871F-065B13077C34Q27321063-19A51FC0-593B-4E59-8A41-5998D59C6D60Q27334358-EBDF8A3D-BAA2-42E7-90F7-9C68F994A80CQ33659753-0D149387-1BBB-4516-A727-8C3495CB3FB9Q33724960-6B022902-1C26-4320-AC64-8736A3DDF55FQ33737949-506FB5EB-C632-4C2D-A8D0-D089697A73E7Q34257253-BDEA47E3-9027-4749-ABA8-481DCC70B8CFQ34511559-18419187-95B0-4806-A2B2-DEEB7566876EQ34566085-3468BEC9-AD68-4F35-9828-EB089EB8665BQ34613574-CD85CEB4-9061-4E2D-99B1-DC241C0D21E0Q35532615-4EC49303-7646-464C-A44E-6F32745537C2Q35890723-896D8D31-DA36-4A86-8FB2-FA7EEA1D53D2Q35960819-94FDE8E3-CD01-4D7C-A5B3-21446BB27F1EQ36831544-8DF27631-0CEC-435B-96CC-58CD27FBEA3FQ37309281-628BAEA8-BC19-49A5-9F9D-935B3FFEC4AFQ38101071-0583B6AF-8B62-4C62-99CE-FFBCF0407E78Q38243220-62B5A982-6F85-4F5A-A53F-D72A482927F7Q38786910-B966B737-6C06-4E78-853D-361DE4F81BFCQ38962473-B4270A79-6DCA-4B01-9C2B-F5222BE79448Q44872017-5236AC37-30AE-45D7-A169-6D50BC1F5378Q47134294-1EFBD403-F2EE-47C2-B670-B3231D382913Q47853580-66D0C206-948F-44F8-B798-2962187D54D6Q47994902-72842F42-BCBF-4AC9-87A7-6E40098E540AQ55210484-8A163784-17CD-4500-BB3B-5722965062E5
P2860
Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Therapeutic vaccination with r ...... mental visceral leishmaniasis.
@ast
Therapeutic vaccination with r ...... mental visceral leishmaniasis.
@en
type
label
Therapeutic vaccination with r ...... mental visceral leishmaniasis.
@ast
Therapeutic vaccination with r ...... mental visceral leishmaniasis.
@en
prefLabel
Therapeutic vaccination with r ...... mental visceral leishmaniasis.
@ast
Therapeutic vaccination with r ...... mental visceral leishmaniasis.
@en
P2093
P2860
P356
P1476
Therapeutic vaccination with r ...... imental visceral leishmaniasis
@en
P2093
Alice Maxwell
Asher Maroof
Barbara Smith
Charles N J Lacey
Deborah F Smith
Florian O Losch
Michael R Hodgkinson
Najmeeyah Brown
Peter Walden
Ulrike Fritz
P2860
P304
P356
10.1093/INFDIS/JIR842
P407
P577
2012-02-01T00:00:00Z